In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides

被引：124

作者：

Van Herrewege, Y

Michiels, J

Van Roey, J

Fransen, K

Kestens, L

Balzarini, J

Lewi, P

Vanham, G

Janssen, P

机构：

[1] Inst Trop Med, Dept Microbiol, Immunol Lab, B-2000 Antwerp, Belgium

[2] Inst Trop Med, Dept Microbiol, AIDS Reference Lab, B-2000 Antwerp, Belgium

[3] Tibotec Virco NV, Mechelen, Belgium

[4] Katholieke Univ Leuven, Rega Inst Med Res, Lab Virol & Chemotherapy, B-3000 Louvain, Belgium

[5] Janssen Pharmaceut, Ctr Mol Design, Vosselaar, Belgium

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2004年 / 48卷 / 01期

关键词：

D O I：

10.1128/AAC.48.1.337-339.2004

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 (Dapivirine) effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission. Both drugs had a favorable therapeutic index. A 24-h treatment with 1,000 nM UC-781 or 100 nM TMC120-R147681 prevented cell-free HIV infection, whereas 10-fold-higher concentrations blocked cell-associated HIV.

引用

收藏

页码：337 / 339

页数：3

相关论文

共 22 条

[1] Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors [J].

Balzarini, J ;

De Clercq, E ;

Carbonez, A ;

Burt, V ;

Kleim, JP .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (06) :517-528

[2] Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent [J].

Balzarini, J ;

Naesens, L ;

Verbeken, E ;

Laga, M ;

Van Damme, L ;

Parniak, M ;

Van Mellaert, L ;

Anné, J ;

De Clercq, E .

AIDS, 1998, 12 (10) :1129-1138

[3]

BALZARINI J, 1992, J BIOL CHEM, V267, P11831

[4] Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor [J].

Borkow, G ;

Salomon, H ;

Wainberg, MA ;

Parniak, MA .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (10) :711-714

[5] Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: Retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase [J].

Borkow, G ;

Barnard, J ;

Nguyen, TM ;

Belmonte, A ;

Wainberg, MA ;

Parniak, MA .

JOURNAL OF VIROLOGY, 1997, 71 (04) :3023-3030

[6] Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1 [J].

Buckheit, RW ;

Hollingshead, M ;

Sinson, S ;

FliakasBoltz, V ;

Pallansch, LA ;

Roberson, J ;

Decker, W ;

Elder, C ;

Borgel, S ;

Bonomi, C ;

Shores, R ;

Siford, T ;

Malspeis, L ;

Bader, JP .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (09) :789-796

[7] PCR-based assay to quantify human immunodeficiency virus type 1 DNA in peripheral blood mononuclear cells [J].

Christopherson, C ;

Kidane, Y ;

Conway, B ;

Krowka, J ;

Sheppard, H ;

Kwok, S .

JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (02) :630-634

[8] Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation [J].

Di Fabio, S ;

Van Roey, J ;

Giannini, G ;

van den Mooter, G ;

Spada, M ;

Binelli, A ;

Pirillo, MF ;

Germinario, E ;

Belardelli, F ;

de Bethune, MP ;

Vella, S .

AIDS, 2003, 17 (11) :1597-1604

[9] CHALLENGES FOR THE DEVELOPMENT OF FEMALE-CONTROLLED VAGINAL MICROBICIDES [J].

ELIAS, CJ ;

HEISE, LL .

AIDS, 1994, 8 (01) :1-9

[10]

FELDBLUM PJ, 1995, AIDS SA, V9, P85